Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lupin Expands US Inhalation Business With Two Sunovion Brands

Indian Firm Pays $75m For US Rights To Respiratory Brands Brovana And Xopenex HFA

Executive Summary

Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.

You may also be interested in...

Lupin Launch In Germany Supports Respiratory Push

Lupin has revealed details of the German launch of its Luforbec (beclometasone/formoterol) branded generic rival to Foster through its local Hormosan subsidiary, as part of the Indian firm’s wider push in the respiratory category.

Lupin Delivers On US Generic Spiriva Approval

Lupin has gained a long-awaited FDA approval for its US generic version of Spiriva. The product is seen as a major element of Lupin’s respiratory franchise and a key contributor to the Indian firm’s fortunes this year.

Lupin Builds Momentum As It Anticipates FDA Action On Spiriva Rival

Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts